Bush K - Search Results

1

What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Bush K, Page MGP. Bush K, et al. J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):113-132. doi: 10.1007/s10928-017-9506-4. Epub 2017 Feb 4. J Pharmacokinet Pharmacodyn. 2017. PMID: 28161807 Review.

2

Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?

Page MG, Bush K. Page MG, et al. Among authors: bush k. Curr Opin Pharmacol. 2014 Oct;18:91-7. doi: 10.1016/j.coph.2014.09.008. Epub 2014 Sep 29. Curr Opin Pharmacol. 2014. PMID: 25277839 Review.

3

Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

Queenan AM, Shang W, Kania M, Page MG, Bush K. Queenan AM, et al. Among authors: bush k. Antimicrob Agents Chemother. 2007 Sep;51(9):3089-95. doi: 10.1128/AAC.00218-07. Epub 2007 Jun 25. Antimicrob Agents Chemother. 2007. PMID: 17591851 Free PMC article.

4

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. Davies TA, et al. Among authors: bush k. Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. doi: 10.1128/AAC.00029-07. Epub 2007 Apr 30. Antimicrob Agents Chemother. 2007. PMID: 17470659 Free PMC article.

5

Critical analysis of antibacterial agents in clinical development.

Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH, Tacconelli E, Thwaites GE. Theuretzbacher U, et al. Among authors: bush k. Nat Rev Microbiol. 2020 May;18(5):286-298. doi: 10.1038/s41579-020-0340-0. Epub 2020 Mar 9. Nat Rev Microbiol. 2020. PMID: 32152509 Review.

6

In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.

Zhang Y, Lin X, Bush K. Zhang Y, et al. Among authors: bush k. J Antibiot (Tokyo). 2016 Aug;69(8):600-4. doi: 10.1038/ja.2016.73. Epub 2016 Jun 29. J Antibiot (Tokyo). 2016. PMID: 27353166

7

Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.

Bush K, Fisher JF. Bush K, et al. Annu Rev Microbiol. 2011;65:455-78. doi: 10.1146/annurev-micro-090110-102911. Annu Rev Microbiol. 2011. PMID: 21740228 Review.

8

New β-lactam antibiotics and β-lactamase inhibitors.

Bush K, Macielag MJ. Bush K, et al. Expert Opin Ther Pat. 2010 Oct;20(10):1277-93. doi: 10.1517/13543776.2010.515588. Expert Opin Ther Pat. 2010. PMID: 20839927 Review.

9

Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae.

Bush K. Bush K. Curr Opin Microbiol. 2010 Oct;13(5):558-64. doi: 10.1016/j.mib.2010.09.006. Epub 2010 Oct 1. Curr Opin Microbiol. 2010. PMID: 20920882 Review.

10

Tackling antibiotic resistance.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. Bush K, et al. Nat Rev Microbiol. 2011 Nov 2;9(12):894-6. doi: 10.1038/nrmicro2693. Nat Rev Microbiol. 2011. PMID: 22048738 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

639 results

Search Page